Candel therapeutics announces positive final survival data from randomized controlled phase 2 clinical trial of can-2409 in non-metastatic pancreatic cancer

Needham, mass., feb. 25, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final overall survival data from the completed randomized controlled phase 2 clinical trial of can-2409 plus valacyclovir (prodrug), together with standard of care (soc) chemoradiation, followed by resection, in patients with borderline resectable pdac.
CADL Ratings Summary
CADL Quant Ranking